Login to Your Account



Seagen walks away from Immunomedics, $2B IMMU-132 pact; focus on in-house ADCs

By Marie Powers
News Editor

Friday, May 5, 2017

Seattle Genetics Inc. pulled the final thread out of a tie-up that's been unraveling for weeks by consenting to terminate the license agreement it forged in February with Immunomedics Inc. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription